Background Adenocarcinoma of the colon is a common cancer and the annual incidence is increasing. Treatment is essentially surgical, combined with adjuvant chemotherapy in advanced cases. Methods This is a retrospective study of 100 patients with non-metastatic colon adenocarcinoma, treated at the gastroenterology and oncology centre in Ibn Rushd Hospital, Casablanca, over a period of 5 years from January, 2006, to January, 2010. Diagnosis was made after a histological study of biopsies taken during colonoscopy. Findings One hundred patients were diagnosed with non-metastatic colon adenocarcinoma. The sex ratio was 3:2 (M:F), the average age was 52 years, and approximately 50% of patients were diagnosed after a period of 7 months from the appearance of their first symptoms of rectal bleeding events, melena, and dysentery syndrome. Histologically, non-metastatic colon adenocarcinoma is well-differentiated in 80% of cases. All patients were operated on. The distribution of patients by stage was: 61% classified as stage II, 30% stage III, and 9% stage I. Adjuvant chemotherapy FUFOL, FOLFOX IV, or capecitabine was given in 85% of patients and monitoring without adjuvant therapy in 15%. The immediate follow-up after completion of chemotherapy showed complete remission in 95% of patients and 5% were in disease progression. After a mean follow-up of 30 months, 71% were in remission. 18% had a local or metastatic recurrence treated by second line chemotherapy (FOLFIRI or XELIRI), with remission seen in three patients, stable disease in seven patients, and treatment failure in eight patients. Interpretation The multidisciplinary approach to all stages of the process requires the involvement of various disciplines to give the patient the best quality of care. Adenocarcinoma of the colon is a common cancer and the annual incidence is increasing. Treatment is essentially surgical, combined with adjuvant chemotherapy in advanced cases. This is a retrospective study of 100 patients with non-metastatic colon adenocarcinoma, treated at the gastroenterology and oncology centre in Ibn Rushd Hospital, Casablanca, over a period of 5 years from January, 2006, to January, 2010. Diagnosis was made after a histological study of biopsies taken during colonoscopy. One hundred patients were diagnosed with non-metastatic colon adenocarcinoma. The sex ratio was 3:2 (M:F), the average age was 52 years, and approximately 50% of patients were diagnosed after a period of 7 months from the appearance of their first symptoms of rectal bleeding events, melena, and dysentery syndrome. Histologically, non-metastatic colon adenocarcinoma is well-differentiated in 80% of cases. All patients were operated on. The distribution of patients by stage was: 61% classified as stage II, 30% stage III, and 9% stage I. Adjuvant chemotherapy FUFOL, FOLFOX IV, or capecitabine was given in 85% of patients and monitoring without adjuvant therapy in 15%. The immediate follow-up after completion of chemotherapy showed complete remission in 95% of patients and 5% were in disease progression. After a mean follow-up of 30 months, 71% were in remission. 18% had a local or metastatic recurrence treated by second line chemotherapy (FOLFIRI or XELIRI), with remission seen in three patients, stable disease in seven patients, and treatment failure in eight patients. The multidisciplinary approach to all stages of the process requires the involvement of various disciplines to give the patient the best quality of care.
Read full abstract